Current CIBMTR Cell Therapy Studies
| Company | Novartis | Kite | Kite | BMS/Celgene | BMS/Celgene | BMS/Celgene | Janssen/Legend | Adaptimmune |
|---|---|---|---|---|---|---|---|---|
| Product name | Kymriah | Yescarta | Tecartus | Breyanzi | Abecma | n/a | Carvykti | Tecelra |
| Scientific name | Tisagenlecleucel | Axicabtagene ciloleucel | Brexucabtagene autoleucel | Lisocabtagene maraleucel | Idecabtagene vicleucel | Non-conforming Liso-cel and Ide-cel | Ciltacabtagene autoleucel | Afamitresgene autoleucel |
| Other name | CTL019 | KTE-C19 | KTE-X19 | JCAR017 | BB2121 | JCAR017 & BB2121 | BCMA | n/a |
| FDA approval date | 3/20/2017 (ALL) 5/1/2018 (DLBCL) 5/27/2022 (FL) |
10/18/2017 | 7/24/2020 (MCL) 10/1/2021 (ALL) |
2/5/2021 (DLBCL) 3/14/2024 (CLL) 5/15/2024 (FL) 5/30/2024 (MCL) |
3/26/2021 | n/a | 2/28/2022 | 8/1/2024 |
| Disease | LYM ALL |
LYM FL |
Mantel cell LYM ALL |
LYM | MM | LYM MM |
MM | Synovial sarcoma |
| Study ID | SC17-08 | SC17-07 | CS20-03 | SC18-04 | SC19-10 | CS20-36 | SC19-09 | CS21-177 |
| Package insert | Kymriah | Yescarta | Tecartus | Breyanzi | Abecma | n/a | Carvykti | Tecelra |
| Reporting guide? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | TBD |
Enrollment into these cellular studies is done when the product name is reported on the F4000. No additional consent is required. These studies fall under the current CIBMTR Research Database consent form, which include HCT and cell therapy language.
Additional reporting guides are available for these studies on the CIBMTR Portal and contain extra information that is product specific and not part of the Forms Instruction Manuals. Some pages also contain recordings of the site initiation meetings.
Last modified:
Mar 25, 2025